Filing Flows › Comparisons › KYMR vs AUTL
Kymera Therapeutics vs Autolus Therapeutics: KYMR and AUTL compared
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $45.7M for Autolus Therapeutics (Q2 2026). Kymera Therapeutics is growing faster (+466% against +118% a year earlier). Autolus Therapeutics is more profitable, with an operating margin of -95.9% against -116.3%.
Where the money goes: KYMR and AUTL
Kymera Therapeutics (KYMR) · Q2 2026
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Autolus Therapeutics (AUTL) · Q2 2026
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
| Kymera Therapeutics (KYMR) | Autolus Therapeutics (AUTL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $65.0M | $45.7M |
| Revenue growth, Y/Y | +466% | +118% |
| Operating margin | -116.3% | -95.9% |
| Net earnings | −$61.2M | −$39.1M |
| Net margin | -94.2% | -85.6% |
| Operating cash flow | −$54.1M | −$25.1M |
Where the revenue comes from
Autolus Therapeutics
- Product revenue, net: $45.7M (100%)
- License revenue: $17K (0%)
Questions
Which is bigger, Kymera Therapeutics or Autolus Therapeutics?
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $45.7M for Autolus Therapeutics (Q2 2026).
Is Kymera Therapeutics or Autolus Therapeutics growing faster?
Kymera Therapeutics is growing faster (+466% against +118% a year earlier).
Which is more profitable, Kymera Therapeutics or Autolus Therapeutics?
Autolus Therapeutics is more profitable, with an operating margin of -95.9% against -116.3%.
More: Kymera Therapeutics earnings · how Kymera Therapeutics makes money · Autolus Therapeutics earnings · how Autolus Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.